Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myrecil
- Development stage
- Unknown
- Lead developer
- Weir Group
- Administration
- Oral, Topical, Vaginal
01
Overview
Myrecil is a patented, plant stem cell-derived bioactive ingredient developed by WEIR Science Ltd for the treatment of genitourinary syndrome of menopause (GSM). As a biotechnology-derived botanical compound, it is utilized as the key active component in both oral supplements and topical cream formulations designed to alleviate symptoms such as vaginal dryness, burning, itching, and dyspareunia. Myrecil is currently being evaluated in a randomized, double-blind, placebo-controlled clinical trial in New Zealand to establish its efficacy and safety as a non-hormonal therapeutic option or adjunct to hormone replacement therapy (HRT).
- Brand names
- Myregyna
Beyond the preview
Go deeper on Myrecil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myrecil.